Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: Results from the prostate cancer prevention trial

Cancer Prevention Research

Volumn 6, Issue 2, 2013, Pages 91-99

  Neuhouser, Marian L ^a   Platz, Elizabeth A ^b   Till, Cathee ^a   Tangen, Catherine M ^a   Goodman, Phyllis J ^a   Kristal, Alan ^a   Parnes, Howard L ^c   Tao, Yuzhen ^d   Figg, William D ^c   Lucia, M Scott ^e   Hoque, Ashraful ^f   Hsing, Ann W ^c   Thompson, Ian M ^g   Pollak, Michael ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; FINASTERIDE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS; SOMATOMEDINS;

EID: 84874496227     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0250     Document Type: Article

References (37)

1. Pollak M. Insulin and Insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
2. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5.
3. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
4. Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science 1998;279:563-6.
5. Signorello LB, Brismar K, Bergstrom R, Andersson SW, Wolk A, Trichopoulos D, et al. Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst 1999;91:1965-7.
6. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman U, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
7. Harman S, Metter E, Blackman M, Landis P, Carter H. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
8. Chokkalingam AP,McGlynn KA,Gao YT, Pollak M, Deng J, Sesterhann IA, et al. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res 2001;61:4333-6.
9. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-109.
10. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4.
11. Hsing AW, Chua S, Gao YT, Gentzschein E, Change L, Deng J, et al. Prostate cancer risk and serum levels of insulin and leptin: a population- based study. J Natl Cancer Inst 2001;93:783-9.
12. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007;16:1121-7.
13. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak MD, et al. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev 2008;17:252-4.
14. Price AJ, Allen NE, Appleby PN, Crowe FL, Travis RC, Tipper SJ, et al. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2012;21:1531-41.
15. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-71.
16. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
17. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33.
18. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Can Prev Res 2008;1:167-73.
19. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst Monogr 2007;99:1375-83.
20. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T, et al. Interrelationships between plasma testosterone, SHBG, IGF-1, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003;13:309-15.
21. Nyomba B, Berard L, Murphy L. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationships with IGF binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997;82:2177-81.
22. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, et al. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev 2005;14:727-30.
23. Neuhouser ML, Kristal AR, McLerran D, Patterson RE, Atkinson J. Validity of short food frequency questionnaires used in cancer chemoprevention trials: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 1999;8:721-5.
24. Neuhouser ML, Kristal AR, Patterson RE, Goodman PJ, Thompson IM. Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutr Cancer 2001;39:12-18.
25. Kristal AR, Arnold KB, Neuhouser ML, Goodman PJ, Platz EA, Albanes D, et al. Diet, supplement use, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2010;172:566-77.
26. Lohman T, Roche A, Martorell M. Anthropometric standardization reference manual.Champaign IL: Human Kinetics Books; 1988.
27. Expert Panel on the Identification Evaluation and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Am J Clin Nutr 1998;68:899-917.
28. Satia-Abouta J, Patterson RE, Schiller RN, Kristal AR. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med 2002;34:493-501.
29. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
30. Yu H, Rohan T. Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
31. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjønneland A, et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008;98:1574-81.
32. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1: The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer; 1980.
33. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JKV, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007;104:5563-8.
34. Miyako K,Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, et al.PAPA- 1 is a nuclear binding partner of IGFBP-2 and modulates its growthpromoting actions. Mol Endocrinol 2009;23:169-75.
35. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012;18:40-50.
36. Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 2011;71:5754-64.
37. Wu J, Haugk K, Woodke L, Nelson PS, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006;99:392-401.